ASH News Daily - Saturday, December 10, 2011 - (Page B-15)

EXPLORING CARFILZOMIB I N R E L A P S E D M U LT I P L E M Y E L O M A ASPIRE: a Phase III trial investigating carfilzomib-based combination therapy • ASPIRE* compares carfilzomib plus lenalidomide and dexamethasone (CRd) and lenalidomide and dexamethasone (Rd) • The trial includes patients with multiple myeloma who have received 1 to 3 prior treatment regimens ASPIRE is one of many ongoing trials investigating agents in the Onyx proteasome inhibitor pipeline. To learn more about the ASPIRE trial, visit www.OnyxTrials.com or www.clinicaltrials.gov . *ASPIRE: cArfilzomib, lenalidomide, and dexamethaSone (CRd) versus lenalidomide and dexamethasone (Rd) for the treatment of PatIents with Relapsed multiple myEloma. ©2011 Onyx Pharmaceuticals, Inc., South San Francisco, CA 1110-CARF-043-R1 June 2011 CARFILP-3280_M02_Updated_ASPIRE_ASH_News_Daily.indd 1 CARFILP-3280_M02_Updated_ASPIRE_ASH_News_Daily.indd FROM: mrodriguez3067 PRINTED @: None 10/24/11 1:37 PM SAVED @: 10-24-2011 1:28 PM BY: Marie Antoinette Rodriguez / Helena Ortiz-Krablin 

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com